Month: September 2026

No Shares Issued; Company Has No Warrants Outstanding Following Cancellation

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — Chaince Digital Holdings Inc. (Nasdaq: CD) (“Chaince Digital” or the “Company”) (formerly Mercurity Fintech Holding Inc.), a digital finance and technology company focused on tokenization, on-chain innovation, and regulated brokerage services, today announced that it has entered into and closed the transactions under a Warrant Repurchase Cancellation and Release Agreement (the “Agreement”) with the holders of the warrants issued in its private placement priced on November 30, 2023 (the “Holders”). The Agreement was executed and the transaction closed on September 21, 2026.

Under the Agreement, the Company repurchased and permanently canceled all of the warrants held by the Holders for aggregate cash consideration of US$2.0 million. No shares were issued in the transaction, and none of the warrants had been exercised. The Holders also released the Company and certain related persons from claims arising from the warrants, subject to the exceptions set forth in the Agreement. As a result of the cancellation, the Company no longer has any contractual obligation to issue or reserve ordinary shares under the warrants, eliminating the potential dilution associated with them.

Following the cancellation, the Company has no warrants outstanding.

Shi Qiu, Chief Executive Officer of Chaince Digital Holdings Inc., commented, “We retired the warrants held by the Holders in full for a fixed cash payment, without issuing a single new share. We believe the transaction represents a disciplined use of capital, and that a capitalization with no warrants outstanding is more straightforward for shareholders to evaluate as we continue to execute on our tokenization, on-chain innovation and regulated brokerage strategy.”

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which will be filed as an exhibit to a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission (the “SEC”) and will be available on the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Chaince Digital Holdings Inc.

Chaince Digital Holdings Inc. (Nasdaq: CD) is a digital finance and technology company focused on tokenization, on-chain innovation, and regulated brokerage services. Through its subsidiaries, including Chaince Securities, LLC, a FINRA-registered broker-dealer, and AI/HPC infrastructure platforms, Chaince Digital provides technology-enabled solutions across distributed computing, business consulting, and capital markets services. The Company aims to bridge traditional financial markets with the emerging digital-asset economy through compliant, scalable, and institutional-grade infrastructure. For more information, please visit www.chaincedigital.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to statements regarding the anticipated benefits of the warrant repurchase and cancellation, the Company’s capital structure and the Company’s business strategy and growth initiatives. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.

Contacts:

International Elite Capital Inc.Annabelle Zhang
Tel: +1(646) 866-7928
Email: chaince@iecapitalusa.com

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, today announced a strategic AI partnership with Softtek, a global software engineering partner. As organizations accelerate AI adoption, many struggle to translate workforce transformation plans into operational reality. Together, WTW and Softtek help clients connect workforce strategy, organizational change and technology implementation to deliver transformation at scale.

WTW’s AI Workforce Transformation solution helps organizations assess the AI potential within jobs, redesign work, plan for workforce management, align total rewards and prepare employees for change.

Softtek turns workforce transformation decisions into operational reality. It applies its engineering, AI and automation expertise to redesign business processes and deploy solutions at scale. Softtek also provides the governance, integration and oversight needed to support reliable enterprise adoption.

Julie Gebauer, WTW President, Health, Wealth & Career said, “Together, WTW and Softtek, can bridge the gap organizations face when taking on AI workforce transformation. We make the link from work, people and programmatic change to enterprise technology execution in ways that deliver measurable and sustainable business outcomes.”

Blanca Treviño, President and CEO of Softtek said, “Technology has always changed the way organizations operate. The hardest part is rarely technology itself. It’s helping people, processes, and business priorities evolve together. WTW brings deep expertise in helping organizations navigate that change. Softtek brings the engineering discipline to put those decisions into practice. Together, we help clients turn strategy into outcomes. We call that ‘AI that ships.’”

The partnership reinforces WTW’s position at the intersection of people, work and technology, with Softtek providing implementation capabilities where clients need it.

About WTW
At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success, and provide perspective that moves you.

Learn more at wtwco.com.

About Softtek
Softtek drives results by combining engineering discipline with expert oversight to put AI into production, tied to business outcomes. The pioneer of nearshore, we close the gap between technology and business strategy. Simple. Smart. Reliable.
Learn more at softtek.com or connect with @Softtek on social media.

Media contacts
WTW: jamie.kilduff@wtwco.com
Softtek: karen.liedl@softtek.com

Recognition highlights the strategy and measurable impact behind ABM’s “Driving possibility, together” brand transformation

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility, engineering, and infrastructure solutions, today announced it has won the Brand and Reputation Excellence category in the 2026 Gartner Marketing and Communications Awards for Driving Possibility Together: ABM Rebrand Launch. The global awards program recognizes transformative marketing and communications work that delivers measurable business impact. The award highlights ABM’s enterprise-wide brand transformation, which brought the full breadth of the company’s capabilities and expertise to the forefront, reinforcing its position as a strategic partner delivering integrated, technology-enabled solutions across industries.

Launched through an integrated, “inside-out” strategy designed to first engage ABM team members before taking the new brand to market, the transformation has delivered measurable impact across key audiences. Since the launch, website conversion rates have increased 60%, regular use of ABM’s new Brand Center has reached 75% of staff and management — more than double its initial goal — and digital media and sports sponsorships have generated 40 million impressions, more than twice ABM’s previous average.

“As ABM has evolved, so too has the breadth of our capabilities and the ways we help clients address increasingly complex facility and infrastructure needs,” said Cary Bainbridge, Chief Marketing Officer at ABM. “We saw an opportunity to build a brand that more fully reflects that evolution — bringing our expertise, innovation and integrated solutions to the forefront while giving our teams a stronger platform to tell the ABM story. Seeing that work deliver measurable impact and earn recognition from Gartner is a testament to the team that brought this transformation to life.”

ABM first engaged its people around a shared story, equipping 100+ Brand Champions across the organization to help drive adoption. The external launch brought “Driving possibility, together” to market through a modernized visual identity and digital experience, advertising and public relations, industry-specific messaging, social media, and visibility at trade conferences and speaking engagements, all designed to showcase ABM’s expertise and ability to deliver integrated solutions at scale.

“Driving possibility, together” reflects ABM’s commitment to partnering with clients to modernize their environments and create smarter, more resilient facilities, while bringing together the company’s expertise, innovation, and scale to create better outcomes for clients, people, and communities. Learn more at www.abm.com.

About ABM

ABM (NYSE: ABM) is one of the world’s largest providers of integrated facility, engineering, and infrastructure solutions. Every day, our over 100,000 team members deliver essential services that make spaces cleaner, safer, and more efficient, enhancing the overall occupant experience.

ABM serves a wide range of market sectors including commercial real estate, aviation, mission critical, and manufacturing and distribution. With over $8 billion in annual revenue and a blue-chip client base, ABM delivers innovative technologies and sustainable solutions that enhance facilities and empower clients to achieve their goals. Committed to creating smarter, more connected spaces, ABM is investing in the future to meet evolving challenges and build a healthier, thriving world. ABM: Driving possibility, together.

For more information, visit www.abm.com.

MEDIA CONTACT:
Michael Valentino
media@abm.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ff8a1792-7007-49c2-8106-1ee2747315d2

New global agreement brings TuneIn’s extensive live radio, music, sports and podcast offerings to select upcoming models

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — Stingray (TSX: RAY), the world’s leading connected streaming media company, today announced that TuneIn has entered into an agreement with Stellantis, a leading global automaker, to bring the TuneIn application, with its expansive catalog of radio stations and podcasts, directly into select future Stellantis vehicles.

“Stellantis is an incredible partner that shares our vision for creating exceptional in-car experiences,” said Rich Stern, CEO of TuneIn. “Our teams have been working closely together to create an experience that feels like a natural extension of each vehicle while giving drivers seamless access to the world’s best live audio.”

TuneIn will provide Stellantis drivers with easy access to more than 100,000 radio stations, including breaking news and trusted programming from leading local, national and global broadcasters, curated music and more. Additionally, intuitive driver controls will make it easy to play, pause and change audio while on the road.

Bringing TuneIn to Stellantis is part of Stingray’s broader strategy to expand automotive access to its extensive audio catalog. Through this integration, Stingray is positioned to significantly strengthen its global automotive presence and accelerate the rollout of branded in-vehicle audio experiences.

TuneIn is available to listeners around the globe through more than 200 connected devices and 14 automotive brands. For more information, visit TuneIn.com.

About Stingray
Stingray Group Inc. (TSX: RAY), the world’s leading connected streaming media company, delivers the best curated audio and video content to consumers worldwide. As a pioneer in multiplatform streaming and distribution, Stingray’s vast digital content portfolio includes thousands of live audio and radio stations, premium music channels, concerts and music documentaries, karaoke products, as well as ambience and wellness channels. Its offering is distributed via connected TVs, smart speakers, mobile, connected cars and retail. Reaching hundreds of millions of consumers every month, Stingray’s products offer an unparalleled advertising reach, enabling brands to connect with an engaged audience across the world. Home to globally renowned brands such as TuneIn, Singing Machine, Stingray Karaoke and Qello Concerts, Stingray is powered by a worldwide team of more than 1,000 employees. For more information, visit www.stingray.com. 

About TuneIn
TuneIn, Stingray’s streaming audio platform, brings together live sports, news, radio, music, audiobooks and podcasts from around the globe, empowering listeners to “hear” what they love wherever “here” might be. With more than 75 million monthly active users and distribution across 200 platforms and connected devices, TuneIn is one of the most widely used streaming audio platforms in the world. TuneIn Premium subscribers get live NFL and college sports programming, exclusive access to commercial-free news from top networks like CNN, Fox News Radio, MS NOW, CNBC and Bloomberg and commercial-free music channels to fit any mood. For more information, please visit us at www.tunein.com or follow us on Facebook, Instagram or Twitter.

CONTACT: For more information, please contact:

Frédérique Gagnier
Director, Communications and Partnerships
Stingray
fgagnier@stingray.com

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is hosting its first Investor Day today, September 24, 2026, at its Cronos Growing Company Inc. Kingsville location.  
  
Presentation materials can be accessed on the Company’s Investor Relations website under Events & Presentations at: https://ir.thecronosgroup.com/events-presentations

The session will be webcast today starting at 12:00 p.m. ET. Webcast registration is now open at: https://dpregister.com/sreg/10211885/104dd78be04.

After the event, a recording of the webcast will be archived for replay on the Company’s website at: https://ir.thecronosgroup.com/events-presentations, and available for 12 months thereafter. 

About Cronos 
Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach^®, PEACE NATURALS^®, LIT™ and Lord Jones^®. For more information about Cronos and its brands, please visit: thecronosgroup.com. 

For further information, please contact:   
  
Media Relations Contact:   
Emily Whalen   
Communications   
Tel: (416) 504-0004   
media.relations@thecronosgroup.com  
  
Investor Relations Contact:  
Harrison Aaron   
Investor Relations   
Tel: (416) 504-0004   
investor.relations@thecronosgroup.com  

To Benefit Select Ronald McDonald House Chapters in the U.S.

LITTLE ROCK, Ark., Sept. 24, 2026 (GLOBE NEWSWIRE) — (NYSE: DDS) Dillard’s is pleased to further its commitment to Ronald McDonald House® with Dillard’s 32^nd annual holiday fundraiser. Since 1994, Dillard’s has supported Ronald McDonald House families with a fundraiser benefiting select Chapters across the United States.

The Southern Living Christmas Cookbook benefiting Ronald McDonald House^® is now available exclusively at Dillard’s.

Create some magic with this all-new cookbook from Southern Living, featuring inventive recipes and holiday decorating ideas. Find inspiration from Southern Living stylists using pieces from the Southern Living Home Collection, exclusively at Dillard’s. With 100+ brand-new recipes and 115+ full-color photos throughout, this Christmas 2026 cookbook is the must-have resource for entertaining with elegance and ease this holiday season.

The cookbook is available now in all Dillard’s stores nationwide and online at dillards.com for just $15. Profits from the sale of the cookbook will benefit select Ronald McDonald House Chapters in Dillard’s markets in the U.S.

“In 2026, Ronald McDonald House provided more than 2.9 million overnight stays for families with children who are ill or injured around the world,” said Lauren Biedron, Global Chief Philanthropy Officer at Ronald McDonald House. “We’re incredibly grateful for Dillard’s continuous support of our mission through the sale of their Southern Living Christmas Cookbook.”

Now in its 32^nd year of support, Dillard’s has raised more than $16.3 million to benefit Ronald McDonald House. “Our continued relationship with Ronald McDonald House gives all of us at Dillard’s an enormous sense of pride. We look forward to another successful fundraiser this year and are honored to support Ronald McDonald House programs in our communities,” said Denise Mahaffy, Senior Vice President of Dillard’s.

Ronald McDonald House is an independent, nonprofit 501(c)(3) organization that cares for families when they have children who are ill or injured. Through a global network of 250 independently operated Chapters in more than 60 countries and regions, we surround families with the resources, services, and support they need, removing barriers so they can be at the heart of their child’s care and ensure the best possible health outcomes. For more information, visit ronaldmcdonaldhouse.org.

Dillard’s was founded by William T. Dillard in 1938 in Nashville, Arkansas, with an $8,000 investment in a hometown department store. Today, Dillard’s, Inc. ranks among the nation’s largest fashion retailers – operating 272 Dillard’s stores, including 28 clearance centers, spanning 30 states and an Internet store at dillards.com. The Company focuses on delivering style, quality, and value to its customers by offering premium fashion apparel, beauty, and home collections from national and exclusive brand sources. Dillard’s complements this curated product assortment with exceptional, client-focused customer care.

CONTACT:
Julie Guymon
Dillard’s
501.376.5965
julie.guymon@dillards.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8a37c2e5-bdbd-4d2e-865d-7a39bfaa9b0e

Proposed Transaction Contemplates Strategic Combination Designed to Expand NGCG’s International Growth Opportunities in the Natural Resources Sector

SCOTTSDALE, Ariz., Sept. 24, 2026 (GLOBE NEWSWIRE) — New Generation Consumer Group, Inc. (OTC: NGCG), a leader in technology-driven infrastructure and scalability solutions, today announced that it has entered into a Letter of Intent (“LOI”) with Nutrien Mineral Limited, a Uganda-based mineral development company, regarding a proposed strategic business combination and reverse merger transaction.

The non-binding LOI establishes a framework for both parties to conduct reciprocal due diligence and negotiate definitive agreements related to a potential transaction designed to create a combined publicly traded enterprise under the NGCG platform.

Under the preliminary terms of the LOI, the parties are evaluating a transaction structure whereby NGCG would hold a proposed 51% ownership interest in the agreed transaction structure or combined business vehicle. The contemplated structure is intended to facilitate the consolidation and reporting of the combined business through NGCG’s public company reporting framework.

As part of the proposed transaction, Nutrien Mineral Limited would receive 5% of the issued and outstanding common shares of NGCG, subject to satisfactory due diligence, valuation review, regulatory compliance, and execution of definitive agreements. Additional provisions contemplate Nutrien Mineral Limited’s participation in future capital raises dedicated to supporting the growth and development of the combined enterprise.

The parties have agreed to cooperate in the exchange of audited financial statements and other legal, operational, technical, and corporate information necessary to evaluate the transaction and complete a comprehensive due diligence process.

CEO Commentary

Jacob DiMartino, Chief Executive Officer of New Generation Consumer Group, Inc., stated:

“We believe this proposed partnership with Nutrien Mineral Limited has the potential to position NGCG at the forefront of a significant international growth opportunity. As we continue to build shareholder value, we are focused on identifying transactions that can provide meaningful asset-backed expansion, expanded revenue potential, and long-term scalability. Nutrien’s opportunities within the mineral sector align with our vision for strategic diversification, and we look forward to conducting due diligence as we work toward a definitive agreement that benefits both organizations and our shareholders.”

Next Steps

The proposed transaction remains subject to, among other things:

• Completion of satisfactory reciprocal due diligence;
• Negotiation and execution of definitive agreements;
• Board and shareholder approvals, where required;
• Compliance with applicable legal and regulatory requirements; and
• Satisfaction of customary closing conditions.

There can be no assurance that the parties will enter into definitive agreements or that any transaction contemplated by the LOI will ultimately be completed.

The team at New Generation Consumer Group, Inc., would like to express their sincere gratitude to TradePro Securities for the introduction to Nutrien Mineral Limited.

About New Generation Consumer Group, Inc.

New Generation Consumer Group, Inc. (OTC: NGCG) is focused on identifying and developing scalable revenue-generating business opportunities across emerging technology sectors, with a strategic emphasis on artificial intelligence infrastructure and digital platforms.

About Nutrien Mineral Limited

Nutrien Mineral Limited is a Uganda-based mineral company engaged in the exploration, development, and commercialization of mineral-related opportunities within East Africa.

Safe Harbor / Forward-Looking Statements

​This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements can be identified by the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance,” “future,” or similar expressions. These statements, including those regarding the closing of the Reg A offering, securing private lender financing, pending and future acquisitions of app-based companies, future profitability, and plans to uplist to a senior exchange, are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially due to various factors, including market conditions, the company’s ability to successfully negotiate and close private financing or acquisitions, and general economic conditions. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT:

Investor Relations

New Generation Consumer Group Inc.

Phoenix, Arizona

Email: InvestorRelations@ngcg.com

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — SkyAI, Inc. (Nasdaq: SKYA) (“SkyAI” or the “Company”) today issued the following statement regarding the voting results at the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”).

The SkyAI Board of Directors (the “Board”) recognizes that the Annual Meeting voting results reflect significant concerns among our shareholders, and we take that message seriously. The Board and management are committed to listening carefully, understanding those concerns, and responding constructively.

Informed by our ongoing engagement with shareholders, the Board and management are evaluating actions across capital allocation, corporate governance, and strategic direction. We are also evaluating opportunities to strengthen our communications and engagement with shareholders. The goal of this work is to narrow the discount of the Company’s share price to NAV and enhance value for shareholders.

We look forward to providing an update on our efforts in the coming weeks.

Voting results from the Annual Meeting will be available in the Company’s Form 8-K to be filed with the U.S. Securities and Exchange Commission.

About SkyAI
SkyAI, Inc. (Nasdaq: SKYA), a Solana digital asset treasury, is building a financial platform that will combine stablecoin rails on Solana with AI. For additional information, please visit www.skyai.co.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this release other than statements of historical fact are forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and beliefs, and involve risks and uncertainties that could cause actual results to differ materially.

These risks and uncertainties include, among others: the Company’s ability to successfully execute its Solana treasury strategy; the Company’s ability to successfully execute its AI technology strategy; volatility in the market price of SOL and other digital assets; changes in the regulatory or legal environment; competitive pressures; and general market, economic, and business conditions. Additional risks are described in the “Risk Factors” section of the Company’s filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov. 

Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise these statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Contact

Media Contact
Edelman Smithfield
SkyAI@edelmansmithfield.com

• Group-wide activity integrates advisory, regulatory and methodological expertise across Diginex products and solutions
• Under the leadership of new interim CEO, Archana Kotecha, the intention is to turn insight into practical action and ultimately help clients achieve better, measurable outcomes.
• Johannes Weber named VP of Sustainability Science and Intelligence

LONDON, Sept. 24, 2026 (GLOBE NEWSWIRE) — Diginex Limited (NASDAQ: DGNX) (“Diginex” or the “Company”), a leading provider of Sustainability RegTech solutions, today announced the consolidation of a new, Group-level Subject Matter Expertise (“SME”) Group, bringing together the Company’s scientific, regulatory and methodological expertise to support product development and advisory delivery in order to help clients move from information to insights, leveraging data to drive measurable outcomes and improve performance.

The initiative marks a continued step in Diginex’s business integration strategy, aimed at delivering best-in-class solutions. It extends the integration mandate Archana Kotecha carried as Chief Impact Officer, when she was tasked with bringing the Diginex, Plan A, Matter and The Remedy Project offerings together into unified commercial solutions. Since being appointed interim Chief Executive Officer on August 31, 2026, Ms. Kotecha has moved to build that mandate into a clearer, Group-level capability.

A Group-Wide Initiative for ESG Intelligence, Product Development and Advisory

The SME Group will operate across three core pillars:

Science & Intelligence: bringing together scientific, regulatory and methodological expertise to inform Diginex’s solutions and help translate complex sustainability requirements into actionable intelligence.

Products & Upgrades: embedding subject-matter expertise into product development, methodologies, data logic and future product enhancements.

Advisory Services: applying the Group’s combined expertise to practical client solutions across environmental and human rights challenges, enabling its clients to take strategic and financial decisions based on the data its tools provide.

Johannes Weber has been appointed VP of Sustainability Science and Intelligence.

Johannes Weber is an environmental management and sustainability professional with 14 years of international affairs and business experience advising ministerial and C-level decision-makers at the intersection of innovation and sustainable development.

Prior to his appointment as VP, Sustainability Science and Intelligence at Diginex, he served as the Director of Sustainability Solutions at Plan A in Berlin, where he was responsible for developing the company’s carbon accounting capabilities and advisory services. Prior to his role at Plan A, Johannes was Head of Global Sustainability at Bird Rides. He also spent nearly a decade at the OECD in Paris, where he delivered strategic recommendations to national governments to accelerate green technology uptake and sustainable urban infrastructure.

Management Commentary

“As Chief Impact Officer, I began the work of connecting our expertise more intentionally, ensuring that our products and advisory services draw on the depth of scientific, regulatory and specialist knowledge across the Group. Establishing this as a clearer, Group-level capability is a natural next step,” said Archana Kotecha, Interim Chief Executive Officer of Diginex. “By bringing our scientific, regulatory, and specialist expertise closer to how we develop our products and deliver for clients, we can strengthen our methodologies, turn insight into practical action and ultimately help our clients achieve better, measurable outcomes.”

“I am pleased to take on this role at a moment when clients need scientific and regulatory expertise translated into practical, day-to-day decisions,” said Johannes Weber, VP of Sustainability Science and Intelligence at Diginex. “Our focus in Science & Intelligence is to make sure that expertise doesn’t sit apart from the business; it should shape how our products are built and how our advisory teams support clients on ESG and human rights challenges.”

About Diginex

Diginex Limited (NASDAQ: DGNX) (“Diginex” or the “Company”) is a London-headquartered RegTech business, providing ESG, sustainability and compliance solutions through an integrated platform trusted by global enterprises and financial institutions.

Its portfolio of products and services spans the full sustainability lifecycle, including Diginex ESG (reporting), Plan A (carbon accounting), Matter (data and investment intelligence), Lumen (supply chain risk and traceability), Apprise (worker voice), and The Remedy Project (human rights remediation), combining technology, analytics and advisory services to turn verified data into decision-ready business intelligence.

For more information, please visit the Company’s website: https://www.diginex.com/

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including statements regarding leadership transition and integration of recently acquired businesses. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the parties to consummate the proposed transaction; satisfaction of closing conditions to the consummation of the proposed transaction; the impact of the announcement of the proposed transaction on the Company’s relationships with its employees, existing customers or potential future customers, and the risk factors described in the Company’s 2026 Annual Report on Form 20-F filed with the SEC on August 13, 2026. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events, except as required by law.

Investor Relations

Email: ir@diginex.com
IR Contact – US
Jackson Lin
Lambert by LLYC
Phone: +1 (646) 717-4593
Email: jian.lin@llyc.global

Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil

MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Montreal Heart Institute, recently activated as the first Canadian clinical trial site for the ReVeRA-301 Phase 3 pivotal trial evaluating etripamil nasal spray for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR), has enrolled their first patient. The expansion into Canada advances the multinational study toward its target of 150 patients with treated AFib-RVR events. ReVeRA-301 is evaluating the same 70 mg repeat-dose regimen that is U.S. Food and Drug Administration (FDA)-approved for paroxysmal supraventricular tachycardia (PSVT) as CARDAMYST® (etripamil) nasal spray.

“Activating clinical trial sites and enrolling study participants in Canada are important steps toward advancing ReVeRA-301 and reflect the momentum behind our global enrollment efforts following the recent first enrolled patient in the United States,” said David Bharucha, M.D., PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals. “We are honored to continue our work with the strong Canadian community of cardiovascular investigators and centers with deep experience in atrial fibrillation research.”

“Following the promising Phase 2 data, we are pleased to advance etripamil into this pivotal Phase 3 trial in AFib-RVR,” said Adrian Petzl, M.D., Cardiologist-Electrophysiologist, Montreal Heart Institute, and investigator on ReVeRA-301. “The ability to intervene promptly with a self-administered therapy outside of the emergency department could represent a meaningful change for patients living with this condition. We are excited that the Montreal Heart Institute is at the forefront of this global research initiative.”

About ReVeRA-301

ReVeRA-301 is a Phase 3 multinational, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil nasal spray in approximately 150 patient events with AFib-RVR. Prompted by symptoms, patients will self administer, in a medically unsupervised setting (e.g., at home), the same 70 mg dose of etripamil and repeat-dose regimen that supports the current FDA indication for the treatment of PSVT. Based on safety data demonstrated to date, Milestone is currently pursuing a single-study supplemental new drug application (sNDA) registration pathway for the treatment of AFib-RVR. The primary endpoint for ReVeRA-301 is reduction in ventricular rate (VR) within 30 minutes. The study will also evaluate a key secondary endpoint of symptom improvement via patient-reported outcomes. Clinical trial sites and enrollment information can be found at https://clinicaltrials.gov.

The trial advances research from ReVeRA-201, a multi-center Phase 2, randomized controlled study of the efficacy and safety of etripamil nasal spray for the acute reduction of symptomatic AFib-RVR in an emergency room setting. The clinical trial showed that a single dose of etripamil nasal spray at 70 mg reduced VR and improved both relief of symptoms and treatment satisfaction.

About Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

Atrial fibrillation (AFib) is the most common sustained arrhythmia, affecting over 6 million people in the United States. The prevalence of AFib in Canada is similarly problematic to that in the United States. The Canadian Cardiovascular Society estimates that AFib affects approximately 1-2% of the population, up to approximately 800,000 people in Canada, and represents a substantial and growing public health burden. AFib presents with an irregular heart rate and is classified as paroxysmal, persistent, or permanent. When there is a rapid heart rate during AFib, it is referred to as “atrial fibrillation with rapid ventricular rate (AFib-RVR).”

Market research indicates that 30-40% of patients with AFib experience at least one episode of RVR per year requiring urgent medical attention. These episodes commonly cause palpitations, shortness of breath, and weakness. While AFib is rarely life-threatening, it is a serious condition that often requires treatment and increases the risk of serious complications if not properly managed. Current options for acute AFib-RVR management are limited and often involve an emergency department visit for IV beta blockers, IV calcium channel blockers, or electrical cardioversion.

About CARDAMYST in the United States

CARDAMYST^® (etripamil) nasal spray is approved by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is a novel calcium channel blocker nasal spray designed as a self-administered rapid response therapy for patients, thereby bypassing the need for immediate medical oversight. The product is intended to provide health care providers with a new treatment option to enable on-demand care and patient self-management. This portable treatment may provide patients with active management and a greater sense of control over their condition. CARDAMYST is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT. Currently, etripamil is in Phase 2 development for treatment of PSVT in pediatric patients and Phase 3 development for control of acute atrial fibrillation with rapid ventricular rate (AFib-RVR) in adults. For more information, please visit CARDAMYST.com.

U.S. FDA Indication
CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

IMPORTANT SAFETY INFORMATION FOR CARDAMYST (etripamil)

What is CARDAMYST?

CARDAMYST is a prescription medicine used to help restore normal sinus heart rhythm in adults who have symptoms of sudden episodes of fast heartbeat called paroxysmal supraventricular tachycardia (PSVT).

It is not known if CARDAMYST is safe and effective in children.

Do not use CARDAMYST if you:

• are allergic to CARDAMYST or any of its ingredients. See the Patient Information for a complete list of ingredients in CARDAMYST.
• have limitations in activities due to heart failure (moderate to severe heart failure).
• have Wolff-Parkinson-White (WPW) syndrome, Lown-Ganong-Levine syndrome, or an abnormal heart rhythm pattern called pre-excitation (delta wave) on an electrocardiogram (ECG).
• have sick sinus syndrome without a permanent pacemaker.
• have second degree or higher atrioventricular (AV) block.

Before using CARDAMYST, tell your healthcare provider about all of your medical conditions, including if you:

• have a history of fainting.
• have low blood pressure.
• are pregnant or plan to become pregnant. It is not known if CARDAMYST will harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if CARDAMYST passes into your breast milk. You should stop breastfeeding for 12 hours after treatment with CARDAMYST. During this time, pump and throw away your breast milk. Talk to your healthcare provider about the best way to feed your baby after using CARDAMYST.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of CARDAMYST?

CARDAMYST may cause serious side effects, including:

• Fainting due to CARDAMYST effects on blood pressure, heart rate, and electrical activity of the heart. CARDAMYST may cause dizziness and fainting, especially in people with a history of fainting and certain heart problems, or people with a history of fainting during an episode of PSVT. Use CARDAMYST while sitting in a safe area where you will not fall if you become dizzy or lightheaded. Lie down if you feel dizzy or lightheaded after using CARDAMYST. If fainting occurs after using CARDAMYST, caregivers should place you on your back and seek medical help.

The most common side effects of CARDAMYST include:

nasal discomfort nasal congestion runny nose

throat irritation nosebleed

These are not all of the possible side effects for CARDAMYST. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see the full Prescribing Information 
https://milestonepharma.com/etripamilprescribinginformation.pdf for CARDAMYST.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib-RVR. https://milestonepharma.com/

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “continue,” “could,” “demonstrate,” “designed,” “develop,” “estimate,” “expect,” “may,” “pending,” “plan,” “potential,” “progress,” “will,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding: Milestone’s business strategy and plans; the design, timing, and enrollment of the ReVeRA-301 Phase 3 clinical trial for AFib-RVR, including the anticipated number of patients and sites; the potential for etripamil to serve as a treatment option for patients with AFib-RVR, including as a self-administered therapy; the commercialization and market adoption of CARDAMYST; the development of etripamil for additional indications, including Phase 2 development in pediatric PSVT patients; expectations regarding the efficacy and safety of etripamil for AFib-RVR based on Phase 2 findings; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies, including the FDA; and other statements not related to historical facts. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of Milestone’s clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs and conflicts, and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related to the sufficiency of Milestone’s capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone’s filings with the U.S. Securities and Exchange Commission (SEC), including in its annual report on Form 10-K for the year ended December 31, 2025, under the caption “Risk Factors,” as such discussions may be updated from time to time by subsequent filings Milestone may make with the SEC. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com

Media Relations
Rebecca Novak, rnovak@milestonepharma.com